Stockwinners Market Radar for June 02, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:10 EDT AT&T, CWA reach tentative agreement in West wireline contract negotiations - AT&T announced that Pacific Bell and Nevada Bell have reached a tentative agreement with the Communications Workers of America in West Region wireline contract negotiations covering over 17,000 employees in California and Nevada. Including this agreement, AT&T has reached 30 different labor agreements since 2015, covering about 145,000 employees. The agreement will be submitted to the union's membership for a ratification vote in coming days. Out of respect for union membership, AT&T will not comment on the details of the tentative agreement until it has been presented by CWA leadership to members for a vote.

17:51 EDT CoreSite Realty VP Tobin sells 5,000 shares of company stock - Disclosed in a regulatory filing after the close, CoreSite Realty VP Dominic Tobin sold 5,000 shares of company stock at an average price of $105.61.

17:39 EDT Intelsat receives termination notice from OneWeb - As previously announced, on February 28,, Intelsat entered into a combination agreement, as amended on May 1, with WorldVu Satellites Limited, OneWeb, and, also on February 28, Intelsat entered into a share purchase agreement with SoftBank Group. On June 2, Intelsat received a termination notice from OneWeb pursuant to which OneWeb terminated the Combination Agreement pursuant to Section 9.1(e) thereof and a termination notice from SoftBank pursuant to which SoftBank terminated the Share Purchase Agreement pursuant to Section 7.1(e) thereof. Effective upon delivery of the termination notices to Intelsat, the Combination Agreement and Share Purchase Agreement were terminated and became void and of no further effect, without any liability or obligation on the part of the parties thereto, except as expressly set forth therein.

17:36 EDT HTG Molecular enters amended, restated supply pact with Illumina - According to a regulatory filing, on June 2, 2017, HTG Molecular Diagnostics (HTGM) entered into an Amended and Restated Development and Component Supply Agreement with Illumina (ILMN), effective May 31, 2017, which amends and restates the parties' IVD Test Development and Component Supply Agreement, dated October 15, 2014. The Restated Agreement provides for the development and worldwide commercialization by the Company of nuclease-protection-based RNA or DNA profiling tests for use with Illumina's MiSeqDx sequencer in the field of diagnostic oncology testing in humans. Under the Restated Agreement, the parties will continue activities under the First Development Plan which was entered pursuant to the Original Agreement, and the company may, at its discretion, submit additional development plans for IVD test kits in the Field to Illumina for its approval, not to be unreasonably withheld. Under each development plan, Illumina would provide specified regulatory support and rights, and develop and deliver to the Company an executable version of custom software, which, when deployed on Illumina's MiSeqDx sequencer, would enable sequencing by the end-user of the subject IVD test kit probe library. Illumina retains ownership of the custom software, subject to the company's right to use the custom software in connection with the commercialization of IVD test kits. The company is required to pay Illumina up to $0.6 million in the aggregate upon achievement of specified regulatory milestones relating to the IVD test kits. In addition, the Company has agreed to pay Illumina a single digit percentage royalty on net sales of any IVD test kits that the company commercializes pursuant to the Restated Agreement. Absent earlier termination, the Restated Agreement will expire in May 2027.

17:23 EDT Starboard Value cuts Brink's stake to 5.2% from 6.1%

17:16 EDT Third Point lowers stake in Baxter to 7.5% - On June 1, Third Point sold a portion of their common stock position in Baxter in a block trade. Third Point's decision to sell was a result of portfolio management discussions, as Third Point's position in the common stock had approached concentration limit guidelines due to the significant appreciation since their original investment. Third Point des not currently contemplate further sales for at least 90 days but reserve the right to re-evaluate at any time based on, among other things, performance of the Issuer and market conditions. The Reporting Persons are pleased with the performance of the Issuer's CEO and are confident in his ability to continue to create value for shareholders.

17:08 EDT Destination Maternity, Orchestra-Premaman merger on track - Destination Maternity and Orchestra-Premaman announced that they continued to make progress toward their merger, which remains on track to close during Destination Maternity's third fiscal quarter of 2017. Work is proceeding on the preparation of the registration statement on Form F-4 to be filed with the Securities and Exchange Commission covering the shares of Orchestra- Premaman, represented by American Depositary Shares, to be transferred to holders of Destination Maternity shares in exchange therefor upon completion with the merger, as well as the coordinated filing with Orchestra-Premaman's French regulator, the Autorite des marches financiers. Both companies continue to work through the regulatory process, as well as pre-closing integration planning. The public SEC filing is expected to follow the filing of Orchestra-Premaman's audited financial statements as of and for the year ended February 28, 2017, which, under French regulation, are to be filed by June 30, 2017. The merger remains subject to other customary closing conditions, including receipt of the required approval of both Destination Maternity's and Orchestra Premaman's shareholders. Both companies remain confident in the completion of the merger, which is targeted to close by the end of Destination Maternity's third fiscal quarter of 2017.

17:01 EDT EC approves Bristol-Myers' Opdivo for treatment of mUC - Bristol-Myers Squibb announced that the European Commission has approved Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. Today's decision makes Opdivo the first Immuno-Oncology agent approved in the European Union for the treatment of patients with this common type of bladder cancer. "Bladder cancer has an estimated 151,000 new cases diagnosed annually in Europe, yet there have been few advancements in treatment for advanced bladder cancer during the last few decades," said Prof. Dr. Margitta Retz, Director of the Division Uro-Oncology of the Department of Urology, Technical University Munich, Germany. "The European Commission's approval of nivolumab marks a significant advancement, with a notable objective response rate, and provides an important option to help patients with previously treated locally advanced unresectable or metastatic urothelial cancer."

16:47 EDT Conduent picks Florham Park, NJ as its global headquarters - Conduent Incorporated (CNDT) has elected Florham Park, N.J. as its global headquarters, holding a ribbon-cutting ceremony today at 100 Campus Drive. Conduent completed its separation from Xerox (XRX) at the beginning of 2017 to create a $6.5B business with approximately 90,000 employees focused on 18 industry sectors in more than 40 countries. The company currently has more than 2500 employees in multiple locations in New Jersey and has plans for continued growth throughout the state.

16:41 EDT Cleveland Biolabs principial financial officer Szydlo to resign - According to a regulatory filing, on May 29, 2017, John Szydlo notified Cleveland Biolabs that he will resign as the company's Principal Financial Officer, effective June 16, 2017, in order to accept a senior executive position at another company. Following Mr. Szydlo's resignation, Yakov Kogan, the company's Chief Executive Officer, will serve as the interim Principal Financial Officer, effective June 16th, while the company searches for a replacement for Mr. Szydlo. Information regarding Dr. Kogan's background and business experience, contracts between the company and Dr. Kogan and any related party transactions involving Dr. Kogan is incorporated by reference herein from the company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 3, 2017. Szydlo will continue to be employed by the company to assist with the transition of his duties for a period of approximately one week after the effective date of his resignation from the office of Principal Financial Officer. Szydlo's decision to resign was not due to any disagreement relating to the company's management, policies, or practices.

16:30 EDT NewLink Genetics trading resumes

16:26 EDT Stephen D. Baksa reports 4.9% stake in SITO Mobile - Stephen D. Baksa, who holds a 4.9% stake in SITO Mobile, said in a regulatory filing that, on June 1, 2017, the inspector of elections appointed by the company certify the Written Consents previously delivered by the reporting persons delivered its final report in which it certified that Written Consents with respect to 11,963,654 shares of Common Stock were voted in favor of the Proposals. SITO informed Baksa that it does not intend to contest the certified tabulation of the inspector of elections.

16:16 EDT Morgan Stanley reports 5.1% passive stake in Rosetta Genomics

16:08 EDT Myriad announces 17 new health insurance plans covering EndoPredict - Myriad Genetics announced that multiple new insurance plans have announced positive coverage policies for EndoPredict. Recently, Blue Shield of California, Humana and multiple regional plans announced positive coverage decisions for the test. Additionally, Highmark Blue Cross Blue Shield, Independence Blue Cross, and Health Care Service Corporation have posted positive coverage policies which take effect in July 2017. Combined, these plans represent greater than 35 million additional covered lives for EndoPredict and in aggregate, private plans representing 109 million covered lives, now have positive coverage policies on EndoPredict. Furthermore, on May 4, 2017 Palmetto GBA, which runs the MolDx program for the Centers for Medicare and Medicaid Services posted a positive draft local coverage determination for EndoPredict. If this draft LCD is approved, combined with the current private coverage for the test, EndoPredict would be covered for approximately 75 percent of breast cancer patients in the United States."The ramp in coverage for EndoPredict has been extremely rapid and we are very close to having nearly full coverage for this important test," said Mark C. Capone, president and CEO, Myriad Genetics. "We believe this unprecedented ramp in coverage is reflective of the strong data including the head-to-head study which showed that EndoPredict "markedly outperformed" the first-generation test in breast cancer patients."

16:06 EDT Dynavax: Data for SD-101, KEYTRUDA combo shows ORR of 100% - Dynavax Technologies (DVAX) announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA, an anti-PD-1 therapy developed by Merck (MRK). Results evaluating 19 patients for efficacy and 22 patients for safety were presented in a poster at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago. In 7 anti-PD-1/L1-naive patients, SD-101 used in combination with KEYTRUDA resulted in an overall response rate of 100%, with a complete response rate of 29%. This is a meaningful increase over use of KEYTRUDA alone, which has already shown a 33% ORR, with a 6% CR. In 12 patients with advanced melanoma who had previously failed on anti-PD-1 treatment, introduction of SD-101 resulted in tumor shrinkage in 42% of patients, with 17% having a partial response, indicating an anti-tumor immune response generated by SD-101. The combination of SD-101 and KEYTRUDA in this study, mobilized both innate and adaptive immune response in study participants. Tumor shrinkage was observed in non-injected visceral lesions. "Having 7 out of 7 patients naive to anti-PD-1/L1 treatment responding is very encouraging," said Antoni Ribas, M.D., Ph.D., of the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, and lead investigator. "These results are supported by tumor shrinkage in patients who had previously progressed on anti-PD-1 treatment and by confirmatory laboratory biomarker assessments in tumor biopsies. If these clinical results are sustained in the ongoing trial, this combination, which mobilizes both innate and adaptive immune responses in patients, could represent an important advancement in immuno-oncology." SD-101 in combination with KEYTRUDA generally was well-tolerated.

16:02 EDT NewLink says Phase 2 indoximod study did not meet pre-specified endpoints - NewLink Genetics announced the results from a Phase 2 trial of indoximod in combination with taxane chemotherapy for patients with metastatic breast cancer. Top line data from the study show that the trial did not meet its pre-specified endpoints of a statistically significant difference between the two treatment groups as to progression-free survival, overall survival or objective response rate. "As demonstrated by multiple studies that have been reported since the start of this clinical trial, breast cancer unfortunately remains a challenging disease in immuno-oncology," said Primary Investigator Hatem Soliman MD, Associate Member Breast, Tumor Biology, and Immunology Departments, Chair Clinical Research Advisory Committee, H. Lee Moffitt Cancer Center and Research Institute, Associate Professor, Division of Oncologic Sciences University of South Florida. "We would like to thank all the patients, families, investigators, and research teams who supported the completion of this trial," said Charles J. Link, Jr., M.D., Chairman and CEO of NewLink Genetics. "Independent of these results, we continue to be highly encouraged by indoximod as an IDO pathway inhibitor and look forward to future opportunities to share data from ongoing trials in multiple cancer types including melanoma, prostate cancer, acute myelogenous leukemia, and pancreatic cancer."

15:21 EDT Insys Therapeutics director acquires 4,000 common shares - In a regulatory filing, Insys Therapeutics director Rohit Vishnoi disclosed the purchase of 4,000 common shares of the company at a price of $14.1438 per share.

13:54 EDT Buffalo Wild Wings shareholders elect Marcato nominees to board - Marcato Capital Management which beneficially own approximately 9.9% of the outstanding common shares of Buffalo Wild Wings announced that based on proxies submitted to the independent Inspector of Election for Buffalo Wild Wings' 2017 Annual Meeting of shareholders, preliminary results indicate that BWLD shareholders have elected Marcato's nominees Scott Bergren, Sam Rovit and Mick McGuire to the BWLD Board. Mick McGuire, Managing Partner of Marcato, said, "We are very pleased that our fellow BWLD shareholders recognize that additional change on the Board is warranted to return Buffalo Wild Wings to a path of growth and long-term value creation. We will bring the fresh perspectives, restaurant industry expertise and oversight the BWLD Board needs to spearhead improvements at the Company. Scott, Sam and I are eager to roll up our sleeves, and work closely with the incumbent directors to drive a strategy to make Buffalo Wild Wings a winning company again."

13:19 EDT Seagate says will support ideas, principles outlined in Paris climate agreement - Seagate Technology Chairman and CEO Steve Luczo issued the following statement expressing concern over the United States' withdrawal from the Paris Climate Agreement: "Seagate will continue to support the ideas and principles outlined in the Paris Agreement. A global response to climate change is required, as inaction will be clearly detrimental to humanity and all living species. We will not abdicate our responsibility to lead in this important effort."

13:16 EDT Buffalo Wild Wings initiates CEO search process, Smith to retire by year end - Buffalo Wild Wings announced that Sally Smith has notified the Buffalo Wild Wings board of directors of her decision to retire before the end of the year. Smith will continue to serve as President and CEO until the end of the year or until such time as a successor has been named. The Buffalo Wild Wings board has initiated a search process and will engage a leading executive search firm to assist in identifying a successor. Smith has also withdrawn her candidacy for election to the board in connection with the 2017 annual meeting of shareholders and the board will not be nominating a replacement for Smith, the company announced.

13:07 EDT Baker Hughes reports U.S. rig count up 8 to 916 rigs - Baker Hughes reports the U.S. rig count is up 8 rigs from last week to 916, with oil rigs up 11 to 733, gas rigs down 3 to 182, and miscellaneous rigs unchanged at 1.

12:58 EDT IntercontinentalExchange sees FY17 data revenue at leas' 6% in constant currency - Sees FY17 adjusted expenses $1.94B-$1.98B. Sees FY17 expense synergies roughly $60M. Sees FY17 CapEx $280M-$300M. Sees FY17 interest expense about $44M-$45M per quarter. Sees FY17 effective tax rate 28%-31%. Guidance taken from presentation slides released in a regulatory filing.

12:33 EDT Ampio trading resumes

12:18 EDT Ascena Retail changes Q3 financial release date due to validation work - Ascena retail group announced that it is changing the release date for its Fiscal 2017 third quarter financial results, previously planned for Monday, June 5. The change is to accommodate final review and validation of the previously announced goodwill and intangible asset impairment charge that the Company plans to take in its fiscal third quarter. The Company expects to announce a rescheduled date for its third quarter earnings release and related conference call next week upon completion of final validation work.

12:07 EDT US Foods to acquire F. Christiana, terms not disclosed - US Foods announced that it has agreed to acquire F. Christiana, a broadline distributor of food and food-related products concentrating on the important center-of-the-plate categories as well as dairy and dry goods. Family-owned for three generations, F. Christiana has nearly $100M in annual sales and serves more than 1,800 independent restaurant, hotel, and independent deli/convenience store customers throughout Louisiana, southern Mississippi and parts of southern Alabama. F. Christiana will continue to operate under the F. Christiana name and will remain in the 70,000 square foot facility where it conducts business today. The transaction is expected to close by mid-June. Terms of the transaction were not disclosed.

12:04 EDT Scripps Networks says would need smart strategy to consider consolidation - Comments from Scripps Networks Interactive at Bernstein's 33rd Annual Strategic Decisions Conference

11:56 EDT Digital Ally board terminated stock repurchase program - According to a regulatory filing, on May 31, 2017, the board of directors of Digital Ally terminated the company's stock repurchased program. On August 25, 2015, the board of directors approved such program that authorized the repurchase of up to $2.5M of the company's common stock in the open market, or in privately negotiated transactions. The company did not repurchase any shares of common stock under this Program.

11:42 EDT OPKO Health director acquires 5,000 common shares - In a regulatory filing, Opko Health director John A. Paganelli disclosed the acquisition of 5,000 common shares of the company at a price of $6.168 per share. The transaction is dated June 1, 2017.

11:13 EDT Broadcom report pored over for clues about iPhone 8 - Wireless component supplier Broadcom Limited (AVGO) appeared to indicate yesterday that the rollout of Apple's (AAPL) new iPhone 8 would be slower than the launches of the iPhones that debuted in 2016. However, Broadcom also suggested that it would obtain more revenue from each new model iPhone than the current generation of the device. A number of Wall Street research firms, including JPMorgan, Loop Capital and Craig-Hallum, remain upbeat on Broadcom in the wake of its results and guidance. NEWS: The "initial ramp" of the company's "major North American" customer's next generation phone "[appears] slower this year, compared to prior year," Broadcom CEO Hock Tan said on the company's earnings call, apparently referring to the iPhone 8. He added: "But we believe, this will likely accelerate in our fourth quarter. Our third fiscal quarter outlook reflects this expectation." Asked a follow-up question from an analyst about whether the "slow ramp" comments were a matter of timing or magnitude, Tan replied: "It's timing. I think, it is timing and last year, the similar ramp was earlier -- was stronger in Q3 probably because it was earlier. And here the initial volume in our fiscal Q2 was smaller, made up with content on our side, but definitely Q4 is forecasted to be larger." The amount of content that Broadcom supplies for each iPhone sold will increase 40% versus the last version of the device, the company also indicated. ANALYST REACTION: The 40% increase in Broadcom's content per iPhone was a positive surprise, according to Loop Capital analyst Betsy Van Hees. Broadcom is poised to benefit from its strong position in multiple, varied end markets, while it will also be boosted by its operating leverage, and accretion from its acquisition of Brocade (BRCD), according to Van Hees. She continues to identify the stock as a top pick and raised her price target on the shares to $285 from $270. Broadcom's revenue per iPhone could rise to $16 or more, estimated Craig-Hallum analyst Anthony Stoss. Since the iPhone 8 probably won't be delayed, Broadcom may surpass its guidance for its July quarter by a significant amount, the analyst stated. He raised his price target on the stock to $290 from $260 and reiterated a Buy rating on the name. JPMorgan analyst Harlan Sur raised his price target for Broadcom to $300 from $260, saying diversified growth and Apple iPhone content gains drove the Q2 beat and "strong" Q3 outlook. OLED BEHIND DELAY?: Recent media reports have indicated that leaked photos purportedly showing Apple's "iPhone 8" indicate that the next iteration of its highest-end phone may feature a curved glass OLED screen, no identifiable home button, a stainless-steel chassis and a dual-camera system. However, Apple Insider has reported, citing notes issued by influential KGI Securities analyst Ming-Chi Kuo, that Apple's iPhone 8 may experience supply shortages through the end of 2017 due to the smartphone's expected adoption of new technologies, including its OLED display. The Nikkei Asian Review has recently added that analysts have speculated that OLED handsets could be delivered in late October or November, after the phone's usual September release. BAIRD SURVEY: Meanwhile, Baird analyst William Power tells investors that his Apple survey to gauge demand for the next iPhone shows "solid, though not euphoric" demand, adding that there appears to be higher upgrade interest from older models than in past. Better battery life and wireless charging were the most desired features mentioned by those surveyed, he noted. The survey doesn't change his overall outlook, said Power, who continues to recommend purchase of the stock into the iPhone 8 launch. PRICE ACTION: In morning trading, Broadcom rose 7% to over $251 per share while Apple added 0.4% to $153.73.

10:45 EDT Under Armour 'disappointed' in decision to exit climate agreement - Under Armour CEO Kevin Plank said in a statement to media outlets: "In 2015, the United States signed a contract with all of our closest allies and 194 member nations of the United Nations Framework Convention on Climate Change. I believe in keeping one's word and doing everything possible to execute on our commitments. We at Under Armour are disappointed by the Administration's decision to withdraw from the Paris Climate Agreement as climate change continues to threaten our planet, our cities and our economies. Climate change is real and must be taken seriously by our business community, our customers, our neighbors and our elected officials. Sustainability has always been part of our DNA: it's integral to how we live and work and is essential to our environment. As a business leader concerned with creating American jobs, I disagree with the decision to exit the Paris Accord. Our word matters and it is our collective responsibility to help protect Mother Earth."

10:37 EDT Ally Financial moves higher during presentation at investor conference - CEO Jeffrey Brown is presenting at the Bernstein Strategic Decisions Conference. Shares moved from an intraday low of $18.56 to $18.85 and are now down fractionally while CEO Jeffrey Brown speaks.

10:22 EDT Ally Financial says no longer exposed to one or two OEMs

10:20 EDT FDA posts class 2 recall notice for Exact Sciences Sample Mixer v2 - The Exact Sciences Sample Mixer v2, which is intended for mixing stool samples in a Sample Container as part of pre-analytic sample processing for in vitro diagnostic tests, is being recalled because of incidents of Sample Mixer door damage, which has occurred when the Sample Holder opens during a run and the Sample Holder lid makes contact with the Sample Mixer door. Exact Sciences sent an Urgent Medical Device Correction letter dated April 28, 2017, via email to all affected consignees, according to the FDA. Reference Link

10:15 EDT Ally Financial does income verification for 65% of subprime auto loans

10:12 EDT Icahn gets HSR clearance for Nextlink deal with Verizon - On June 1, the Federal Trade Commission granted Hart-Scott-Rodino Act early termination to a deal between Carl Icahn and Verizon Communications related to the acquisition of Nextlink Wireless by the wireless giant. As previously announced on February 22, 2016, XO Communications (XO) agreed to sell its fiber-optic network business to Verizon for approximately $1.8B. At that time, Icahn, the Chairman and sole shareholder of XO Holdings, said: "Although this sale to Verizon does not represent a significant annualized return on our investment, we believe that in today's environment it does represent the best achievable outcome for the company's customers, employees and owner." Verizon shares briefly spiked in early trading as the FTC notice was circulated.

10:06 EDT Ally Financial says Auto is 'bread and butter' of business - Comments from Ally Financial at Bernstein Strategic Decisions Conference.

10:02 EDT Verizon ticks higher after FTC grants transaction with Carl Icahn

09:47 EDT Einhorn remains 'large holder' of Apple, reduced position 'some' - Greenlight Capital's David Einhorn is speaking on Bloomberg TV.

09:45 EDT Greenlight's Einhorn discussing short position in Tesla - Greenlight Capital's David Einhorn is speaking on Bloomberg TV.

09:43 EDT Einhorn says GM spent $15M to pitch bear case on own shares - Greenlight Capital's David Einhorn is speaking on Bloomberg TV.

09:37 EDT Einhorn says plan for GM could unlock 30%-50% of share value - Greenlight Capital's David Einhorn is speaking on Bloomberg TV.

09:32 EDT AT&T to acquire Vyatta network operating system from Brocade - AT&T (T) announced that it has agreed to buy the Vyatta network operating system and associated assets of Brocade Communications (BRCD). This platform includes the vRouter product line. AT&T also intends to hire certain Brocade employees associated with that business. The deal is expected to close in early summer, subject to closing conditions and prior to the closing of the previously announced proposed acquisition of Brocade by Broadcom Limited (AVGO). After the deal closes, AT&T will own the Vyatta network operating system, including its virtual network functions and distributed services platform, software under development as part of its unreleased roadmap, existing software licenses, and related patents and patent applications. "The Vyatta platform will help AT&T continue to drive its network transformation. We expect to virtualize and software-control 75% of our network by 2020. Our plan is to hit 55% by the end of 2017," AT&T said. Financial terms were not disclosed.

09:26 EDT On The Fly: Pre-market Movers - UP AFTER EARNINGS: Lululemon (LULU), up 15.5%... Canada Goose (GOOS), up 10.9%... Broadcom (AVGO), up 5.8%. ALSO HIGHER: Wayfair (W), up 2.4% after being upgraded to Outperform from Perform at Oppenheimer. DOWN AFTER EARNINGS: VMware (VMW), down 2.4%... RH (RH), down 20.5%... Boot Barn (BOOT), down 17.1%. ALSO LOWER: Endocyte (ECYT), down 30% after announcing it will end clinical development of EC1456 and EC1169 in Taxane-Naive Patients... Whiting Petroleum (WLL), down 2.9% after being downgraded to Neutral from Outperform at Credit Suisse.

09:15 EDT Worthington acquires Amtrol for about $283M - Worthington announced it has acquired Amtrol, a manufacturer of pressure cylinders and water system tanks. The purchase price was approximately $283M. In calendar year 2016, Amtrol had approximately $248M in net sales and adjusted EBITDA of $38.5M.

09:11 EDT Balchem acquires Innovative Food Processors, terms not disclosed - Balchem Corporation (NASDAQ:BCPC) today announced that it has acquired Innovative Food Processors, or IFP, a privately held manufacturer of agglomerated and microencapsulated food and nutrition ingredients, headquartered in Faribault, Minnesota. The financial terms of the transaction were not disclosed.

09:04 EDT Royal Gold announces Peak Gold resource estimate - Royal Gold completed an estimate of mineralized material at the Peak and North Peak deposits located near Tok, Alaska. The estimate of measured and indicated resources contained within mineralized material at a $1,400 per ounce gold pit shell consists of 11.3M tonnes grading 3.46 grams per tonne gold, 14.09 gpt silver, and 0.16% copper. "These initial results are a great start and Peak Gold has identified several additional targets that will be pursued over the balance of the year," commented Tony Jensen, President and CEO of Royal Gold. "We are encouraged by the robust grade and near surface characteristics of the deposits, which are located just a few miles from the intersection of Alaska Highways 1 and 2. We already own a royalty on the project and we will continue to focus on opportunities in the future aligned with our core business model. Peak Gold is progressing as we had hoped it would to this point, and we have appreciated an excellent working relationship with our host community of the Native Village of Tetlin and our joint venture partner, Contango ORE, Inc." The measured and indicated resources were calculated with resource cones at a gold price of $1,200 per ounce with a cut-off grade of 0.5 grams per tonne and at $1,400 gold with a cut-off grade of 0.43 grams per tonne.

08:59 EDT Ingredion reaches labor agreement in Argentina - Ingredion announced that it has reached an agreement with the SOERM labor union in Argentina. "We have to come to a fair and equitable conclusion. Both of our manufacturing facilities in Argentina will remain open and will resume operations on June 4," said Jim Zallie, Ingredion executive vice president and president, Americas. Ingredion has manufacturing facilities in Baradero and Chacabuco and employs 698 people in Argentina.

08:48 EDT Amazon to open fufillment center in Fresno, create 1,500 jobs - Amazon.com announced plans to open its first fulfillment center in Fresno and create 1,500 new full-time jobs. This will be Amazon's fifth fulfillment center in California's Central Valley, with three operating fulfillment centers located in Tracy and Patterson, and a fourth facility under construction in Sacramento. Other Amazon California customer fulfillment facilities are located in San Bernardino, Redlands, Moreno Valley, Rialto, Eastvale and Newark. Additionally, there are more than 460,000 authors, sellers, and developers in California growing their businesses and reaching new customers via Amazon products and services. Amazon employees at the 855,000-square-foot fulfillment center will specialize in handling smaller-sized items such as books, electronic devices and children's toys.

08:36 EDT SenesTech announces hiring of Andrew Altman as COO - SenesTech (SNES) announced the hiring of Andrew Altman as Chief Operations Officer, with primary responsibility for sales, marketing and manufacturing operations. Prior to joining SenesTech, Altman was Vice President and General Manager at IDEXX BioResearch, a provider of biological materials testing and laboratory animal diagnostic services, a division of IDEXX Laboratories (IDXX).

08:34 EDT Owens Realty Mortgage shareholder Freestone calls for 'immediate liquidation' - Freestone Capital Management, which together with its affiliates is the largest shareholder of Owens Realty Mortgage, announced that it has delivered a letter to the Chairman and board of directors of the company, in which it states in part: "We believe that Management should explore the immediate liquidation of the Company to close the value gap between the Company's current market price and our estimated liquidation value, thereby returning capital to the Company's long-suffering investors...We believe that this enormous gap is due to a flawed business model which penalizes shareholders and primarily enriches Management...After more than eight years of poor returns, instead of continuing to bet on unprofitable and risky loans, the Company should recognize reality and return its underperforming capital to its long-suffering shareholders. The Company should liquidate and thereby close the value gap between the Company's current market price of $16.38 and the estimated $23.50 liquidation value."

08:12 EDT PPG completes sale of Plaka business to Knauf, terms not disclosed - PPG announced that it has completed the sale of its Mexico-based Plaka plasterboard and cement-board business to Knauf International GmbH. Financial terms were not disclosed. PPG acquired the Plaka business in 2014 as part of its acquisition of Consorcio Comex, with approximate sales of $30M in 2015, manufactures plasterboard, cement board and drywall primarily for the Mexican construction market. The business employs about 200 people and operates two manufacturing facilities in Queretaro, Mexico.

08:09 EDT Endocyte to halt enrollment in EC1456 trial, cites level of clinical activity - Endocyte plans to stop enrollment in the EC1456 trial, where a careful assessment in folate receptor-positive disease across multiple cohorts of patients and multiple dosing schedules did not yield the level of clinical activity necessary to support continued advancement of this agent. However, enrollment of a small number of patients in the EC1456 ovarian cancer surgical study will continue in order to inform other SMDC programs in development. Preliminary data to-date from the ovarian surgical study provides evidence that patients with FR-positive disease are being successfully identified with the use of the etarfolatide imaging agent, but the intratumoral levels of the EC1456 drug payload may be lower than predicted by pre-clinical models.

08:08 EDT Icahn Automotive to acquire Precision Auto Care, terms not disclosed - Icahn Automotive Group, a wholly-owned subsidiary of Icahn Enterprises (IEP), announced that it has entered into a definitive agreement to acquire automotive service company Precision Auto Care (PACI), parent company of Precision Tune Auto Care. "The acquisition of Precision Auto Care, with more than 250 corporate-owned and franchised Precision Tune service locations in the United States, is the next step in building out our national automotive service network," said Daniel Ninivaggi, CEO of Icahn Automotive Group. "Coupled with our existing footprint of more than 1,000 corporate-owned locations, as well as our in-house automotive parts and tire distribution capabilities, we are uniquely positioned to provide high-quality parts, tires and services to our customers at the most competitive price." Precision Auto Care, in business for more than 40 years, has service locations in 26 states, with concentrations in Georgia, North Carolina and South Carolina.

08:06 EDT Flex Pharma's Phase 2 trial of FLX-787 endorsed by INC - Flex Pharma announced that the Inherited Neuropathies Consortium voted to endorse the company's U.S. Phase 2 Trial of FLX-787 in CMT patients who suffer from cramps. The INC is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in CMT and to improving the care of patients. There are currently no drug products approved in the U.S. for this condition. The company expects to begin enrolling U.S. patients this summer in this randomized, controlled, double-blinded, parallel design study, referred to as the COMMIT trial. FLX-787 is a small molecule co-activator of the TRPA1 and TRPV1 ion channels, and has been shown to suppress muscle cramps in a human model of electrically induced cramps, and to reduce cramping frequency and the associated pain in spontaneously occurring cramps in a population with nocturnal leg cramps. The COMMIT trial is a Phase 2 clinical trial designed to evaluate FLX-787 in patients with CMT who suffer from cramps. This randomized, controlled, double-blinded, parallel design trial in the U.S. will include a run-in period to establish a baseline in cramp frequency. Patients will then be randomized to 30 mg of FLX-787 administered three times a day or control, for 28 days. Patients will be evaluated for changes in cramp frequency as the primary endpoint, with a number of secondary endpoints.

08:05 EDT Mylan announces launch of generic Azilect Tablets - Mylan (MYL) announced the U.S. launch of Rasagiline Tablets, 0.5 mg and 1 mg, a generic version of the reference listed drug, Teva's (TEVA) Azilect Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application, or ANDA, for this product, which is indicated in the treatment of Parkinson's disease.

08:03 EDT Greenlight Capital Re appoints Simon Burton as CEO - Greenlight Capital Re announced it has hired Simon Burton to become its new CEO, effective July 1. Burton will succeed Leonard Goldberg, who will step down as interim CEO while remaining a member of the company's board. Burton will also be appointed to the company's board.

08:03 EDT ViaSat reports successful launch of ViaSat-2 satellite - ViaSat announces the successful launch of its ViaSat-2 satellite aboard an Arianespace Ariane 5 ECA launch vehicle. The Ariane 5 ECA carrying ViaSat-2 lifted off yesterday, June 1 at 4:45 pm PDT from the Guiana Space Center, located in Kourou, French Guiana. Approximately 29 minutes after liftoff, the ViaSat-2 mission was underway with the satellite separating from the launch vehicle. First signals from the satellite were acquired shortly thereafter through a ground station at Hassan, India. ViaSat expects it will take several months for ViaSat-2 to reach its final orbital destination, the company said.

07:47 EDT Air Products announces long-term supply awards from China semiconductor makers - Air Products announced it has recently received multiple, long-term supply awards from semiconductor and flat panel display manufacturers in China. Industrial gases supply contracts awarded to Air Products over the past 12 months call for the investment in six industrial gas plants and a pipeline network for the supply of gaseous nitrogen and oxygen, as well as other bulk gases. These facilities will support existing and new customers in key electronics clusters and industrial parks in China's major economic regions, the company said.

07:33 EDT CME Group reports May average daily volume up 11% to 16.5M contracts - CME Group announced that May average daily volume, or ADV, reached 16.5M contracts, up 11% from May 2016. CME Group May options volume averaged 3.4M contracts per day, up 21% over the same period last year. Open interest at the end of May was 123M contracts, up 9% from the end of May 2016.

07:31 EDT Mylan announces launch of generic Reclast Injection - Mylan (MYL) announced the U.S. launch of Zoledronic Acid Injection, 5 mg/100 mL Single Dose Vial, a generic version of Novartis' (NVS) Reclast Injection. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application, or ANDA, for this product, which is indicated for the treatment of Paget's disease of bone in men and women.

07:12 EDT Myriad Genetics announces results from Study 005 at ASCO - Myriad Genetics announced results from Study 005, a large 2,000 patient prospective study of the Myriad myRisk Hereditary Cancer test, which will be featured in three poster presentations at the 53rd annual meeting of the American Society of Clinical Oncology, or ASCO. The data will be presented by research collaborators from University of Southern California Norris Comprehensive Cancer Center and Stanford University Cancer Institute. The key findings are that more than 50% of the mutations identified were in patients who would not meet current testing guidelines and 34 percent of mutations were identified in unexpected genes, confirming the clinical utility of multi-gene panel testing to improve hereditary cancer-risk assessment.

07:02 EDT Spectrum presents Folotyn, Marqibo clinical data at ASCO meeting - Spectrum Pharmaceuticals announced presentations of clinical data for Folotyn and Marqibo to be presented at the American Society of Clinical Oncology Annual Meeting, being held in Chicago, Illinois, from June 2 to June 6. For more information about the ASCO Annual Meeting and for a complete list of abstracts, please refer to the conference website at http://www.sppirx.com/LinkThrough/LinkThroughASCO.html

07:01 EDT TETRA announces resignation of COO Joseph Elkhoury - TETRA Technologies announced that on June 1, Joseph Elkhoury, its senior vice president and chief operating officer, has resigned for personal reasons. TETRA's President and CEO, Stuart Brightman, has assumed Elkhoury's responsibilities. Elkhoury will continue in a transitional role for a period of time.

06:53 EDT Descartes Systems acquires PCSTrac business for $11.25M in cash - Descartes Systems announced that it has acquired substantially all of the assets of the business of PCSTrac including certain related assets of Progressive Computer Services Inc. dba PCS Technologies. PCSTrac is headquartered in Philadelphia, Pennsylvania. The purchase price for the acquisition was approximately $11.25M in cash.

06:02 EDT Bristol-Myers, Seattle Genetics expand clinical collaboration - Bristol-Myers (BMY) and Seattle Genetics (SGEN) announced that the companies have entered into a collaboration agreement to evaluate the combination of Bristol-Myers Squibb's immunotherapy Opdivo and Seattle Genetics' antibody-drug conjugate, or ADC, ADCETRIS in a pivotal phase 3 clinical trial. The trial will evaluate the combination of ADCETRIS and Opdivo versus ADCETRIS alone as a potential treatment option for patients with relapsed/refractory or transplant-ineligible advanced classical Hodgkin lymphoma, or HL. The combination of ADCETRIS and Opdivo is not approved for the treatment of relapsed/refractory HL. ADCETRIS is an ADC directed to CD30, a defining marker of classical HL, which combines the targeting ability of a monoclonal antibody with the potency of a cell-killing agent. Opdivo is a human programmed death receptor-1 blocking antibody that binds to the PD-1 receptor expressed on activated T-cells and other immune cells.

05:40 EDT Goldman Sachs CEO calls Trump's Paris decision a 'setback' - Goldman Sachs CEO Lloyd Blankfein tweeted last night, "Today's decision is a setback for the environment and for the U.S.'s leadership position in the world."

05:34 EDT Novartis continues to evaluate Kisqali in multiple trials, will present at ASCO - Novartis announced updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative, or HR+/HER2-, advanced or metastatic breast cancer. After an additional 11 months of follow-up, a median progression-free survival, or PFS, of 25.3 months for Kisqali plus letrozole and 16.0 months for letrozole alone was observed. These data will be presented on Sunday, June 4, 2017 at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, in Chicago. These updated results further support that Kisqali plus letrozole improves PFS as a first-line treatment across all patient subgroups. After two years of treatment, the progression-free survival rate was 54.7% in the Kisqali plus letrozole arm compared to 35.9% in patients treated with letrozole alone. In a cohort of 213 U.S. patients treated as part of MONALEESA-2, the median PFS was 27.6 months with Kisqali plus letrozole and 15.0 months with letrozole alone.

04:54 EDT Arianespace announces successful launch of ViaSat-2 - Arianespace said in a press release, "On its sixth successful launch during the first half of 2017, Arianespace set a new heavy-lift record tonight with Ariane 5 in delivering the ViaSat-2 and EUTELSAT 172B telecommunications satellites to geostationary transfer orbit." ViaSat-2 was the second satellite to be launched by Arianespace for ViaSat (VSAT). ViaSat Chairman and CEO Mark Dankberg said Flight VA237's liftoff was "spectacular," and he thanked Arianespace for a "fabulous job." Reference Link